Atrial Natriuretic Peptide Attenuates the Development of Pulmonary Hypertension in Rats Adapted to Chronic Hypoxia

Hongkui Jin, Ren-Hui Yang, Yiu-Fai Chen, Robert M. Jackson, and Suzanne Oparil
Hypertension Program of the Division of Cardiovascular Disease and Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294

Abstract

To test the hypothesis that chronic infusion of atrial natriuretic peptide (ANP) instituted before hypoxic exposure attenuates the development of pulmonary hypertension in hypoxia adapted rats, ANP (0.2 and 1.0 μg/h) or vehicle was administered intravenously via osmotic minipump for 4 wk beginning before exposure to 10% O₂ or to room air. Low dose ANP increased plasma ANP levels by only 60% of vehicle controls after 4 wk and significantly decreased mean pulmonary arterial pressure (MPAP) (P < 0.01), the ratio of right ventricular weight to body weight (RV/BW) (P < 0.01), and the wall thickness of small (50–100 μm) pulmonary arteries (P = 0.01) in hypoxia-adapted rats. ANP did not alter any of these parameters in air-control rats. High dose ANP increased plasma ANP levels by 230% of control and produced greater reductions in MPAP (P < 0.001) and RV/BW (P < 0.05), but not in pulmonary arterial wall thickness, than the low dose. Neither dose of ANP altered mean systemic arterial pressure in either hypoxic or normoxic rats. The data demonstrate that chronic infusion of exogenous ANP at a dose that does not affect MPAP or RV weight in air-control rats attenuates the development of pulmonary hypertension and RV enlargement in rats adapted to chronic hypoxia. (J. Clin. Invest. 1990, 85:115–120.) atrial natriuretic peptide • chronic hypoxia • pulmonary circulation • pulmonary hypertension • rats

Introduction

Preliminary evidence suggests that atrial natriuretic peptide (ANP) may play a role in regulating pulmonary vascular tone (1–4) and may be involved in the pathogenesis of hypoxia-induced pulmonary hypertension (5, 6). Acute hypoxia stimulates the release of ANP from isolated rat and rabbit hearts (6) and increases circulating ANP levels in anesthetized rabbits (5) and pigs (7). Increased plasma ANP levels have been found in rats exposed to chronic hypoxia (8) and in patients with chronic pulmonary hypertension (9). Specific binding sites for ANP have been demonstrated in the lung (10, 11), and ANP is taken up during its passage through the pulmonary circulation (12). Some evidence suggests that ANP has a direct effect on the pulmonary vasculature, causing relaxation of isolated segments of pulmonary artery from the guinea pig, pig, and man in vitro (1, 2). Further, data have been presented that demonstrate that intravenous administration of ANP blunts the pulmonary arterial vasoconstriction induced by acute hypoxia in conscious rats (13) and in anesthesized cats (14), dogs (15), and pigs (7).

Our previous studies (16) demonstrated that ANP reduces pulmonary artery pressure in the rat in vivo, and that this effect is greater in the hypoxia-adapted animals than in air controls. Experiments using the isolated-buffer-perfused lung further demonstrated that the pulmonary depressor effect of ANP in hypoxic rats is due to direct dilation of the pulmonary vasculature (16). The current study tested the hypothesis that chronic infusion of ANP begun before initiation of hypoxic exposure attenuates the development of pulmonary hypertension in hypoxia-adapted rats. Our results demonstrate that chronic infusion of ANP produces a dose-related attenuation in the development of pulmonary hypertension and right ventricular hypertrophy in hypoxia-adapted rats but does not alter either parameter in air controls.

Methods

Male Sprague-Dawley rats were obtained from Charles River Breeding Laboratories, Inc. (Wilmington, MA) at 8 wk of age. Osmotic minipumps (2002 mini-osmotic pump; Alza Corp., Palo Alto, CA) filled with either ANP (1-28; rat; Bachem, Inc., Torrance, CA) to deliver a dose of 0.2 or 1.0 μg/h in 0.1 M acetic acid or the 0.1 M-acetic acid vehicle were implanted in the right jugular vein under ether anesthesia. After recovery from ether, rats were maintained in 10% O₂ at ambient pressure as previously described (17). Age-matched rats were maintained in filtered room air as normoxic controls. Five groups of rats were studied: normoxic + vehicle (n = 14), normoxic + ANP (0.2 μg/h) (n = 8), hypoxic + vehicle (n = 17), hypoxic + ANP (0.2 μg/h) (n = 9), and hypoxic + ANP (1.0 μg/h) (n = 7).

Rats were exposed to hypoxia in a 330-liter plexiglas glove box (Manostat, Brooklyn, NY). Hypoxic exposures (range 10.0±0.5% O₂), were accomplished by adding N₂ (Southern Welding, Birmingham, AL) to the chamber intermittently from a liquid N₂ reservoir, the gas outflow of which was controlled by a solenoid valve activated by the recorder output of an S3-A O₂ analyzer (Applied Electrochemistry, Sunnyvale, CA) through a control circuit (model 371-K; LFE Corp., Clinton, MA). A baralyme (Allied Health Care Products, St. Louis, MO) CO₂ scrubber kept the [CO₂] at < 0.2%. Relative humidity within the chamber was kept at < 70% with anhydrous CaSO₄. Boric acid was used to keep NH₃ levels within the chamber at a minimum. Animals were permitted to have standard laboratory chow and tap water ad lib. Daily animal maintenance was carried out without interruption of the exposures. 2 wk later, the minipumps were exchanged under ether anesthesia.

After intravenous infusion of either ANP or vehicle, and exposure to hypoxia or room air for a total of 4 wk, rats were anesthetized with
pentobarbital sodium (50 mg/kg, i.p.). The trachea was cannulated and the rats were artificially ventilated with a rodent respirator (Harvard Apparatus Co., S. Natick, MA; tidal vol., 1 ml/100 g body wt.; rate, 60 min
1
). Catheters (PE-10 fused to PE-50) filled with heparin-saline solution (50 μm/ml) were implanted into the abdominal aorta through the right femoral artery for measurement of systemic arterial pressure. A thoracotomy was performed, and a similar catheter was inserted into the pulmonary artery through the outflow tract of the right ventricle. The exposed chest was closed with wound clips and sutured. Mean systemic and pulmonary artery pressures were monitored simultaneously through the femoral and pulmonary arterial catheters. After a 30-min period of stabilization, mean systemic arterial pressure (MSAP) and mean pulmonary arterial pressure (MPAP) were recorded. Then, blood (1.5 ml) was collected from the femoral arterial catheter for plasma ANP measurement. Plasma was immediately separated by centrifugation at 4°C and stored at −80°C until RIA for ANP.

The spent minipumps were removed and weighed in order to confirm that they were delivering their contents properly and that the infusate had not run out completely. The infusate samples were stored at −80°C until RIA for ANP. To determine the time course of plasma ANP levels during intravenous infusion of exogenous peptide, minipumps containing ANP (0.2 μg/h) were implanted into the right jugular vein, and catheters were placed in the right femoral artery as previously described in two age-matched air-control rats. Blood (1 ml) was collected from the arterial catheter of conscious rats for ANP measurement 1, 3, 7, 10, and 14 d after minipump implantation. An equal volume of saline was infused to replace the blood loss.

We carried out an additional pilot study to determine the stability of ANP in 0.1 M acetic acid at body temperature in vitro. ANP was dissolved in 0.1 M acetic acid at a final concentration of 0.44 μg/μl, the same as that injected into minipumps for chronic infusion. The ANP solution was placed in a vacuum oven at 37°C, and aliquots (50 μl) were removed after 1, 2, 3, 4, 5, 6, 8, 10, 12, and 14 d and stored at −80°C before ANP measurement.

After removal of blood for ANP assay, the thorax was opened, the left atrium was tied off, a tracheal cannula was inserted, and another cannula was placed in the pulmonary trunk. The lungs were fixed in the distended state by simultaneous infusion of 10% buffered formalin into the pulmonary artery and trachea at 100 and 25 cm H2O pressure, respectively. The cannulas were clamped, and the entire specimen was placed in a bath of 10% buffered formalin for 24 h. Blocks 5-mm thick were taken from the right lower lobe at two-thirds of the distance from the hilum to the pleural surface along the bronchial axis. Sections 5-μm thick were cut for light microscopy, and stained with hematoxylin eosin and Masson trichrome. For each rat, the wall thickness and vessel diameter of at least 25 consecutive arteries (range 50–100 μm) were determined at 450 magnification, using a computerized morphometric system (Biaquant, Nashville, TN) in order to assess the pulmonary vascular effects of the ANP infusion. For statistical analysis, the wall thickness of each artery was expressed as a percent of vessel diameter according to the formula (18): % wall thickness = 2x medial wall thickness/external diameter × 100. Finally, the heart was removed and the atria and major vessels were dissected off by a circular incision. The right ventricular free wall (RV) was dissected from the left ventricle and septum (LV+S). RV and LV+S were weighed immediately. The ratio RV/LV+S was used as an index of the effect of the ANP infusion on pulmonary hypertension in the hypoxic animals.

ANP concentration in plasma or 0.1 M acetic acid measured by a modification of the RIA of Tanaka et al. (19) and Eskay et al. (20). Plasma for ANP determination was extracted with Sep-Pak C-18 cartridges (Waters Associates, Milford, MA) by the method of Eskay et al. (20). Extracts were dried under vacuum and reconstituted in RIA buffer (see below). Rat 8-33 ANP (Peninsula Laboratories, Inc., Belmont, CA) was used as the reference standard. Rabbit anti-rat αANP antiserum was generously donated by Wyeth Laboratories (Philadelphia, PA). During the assay, 10 μl of standard (2-250 pg) or sample were incubated for 48 h at 4°C with 100 μl (8,000 cpm) of 125I-labeled rat ANP (DuPont/New England Nuclear Research Products, Boston, MA), 100 μl of ANP antiserum and 200 μl RIA buffer (50 mM potassium phosphate buffer, pH 7.4, containing 0.1% BSA, 0.01% NaN3, 0.1% Triton X-100, 50 μM PMSF, 50 mM NaCl and 0.0005% aprotonin). Separation of bound from free tracer was done by adding 750 μl of 20% polyethylene glycol-8000 and 75 μl of 1.5% bovine gamma globulin to each assay tube and centrifuging for 1 h at 2,200 g (21). Recovery of ANP from plasma, as assessed by addition of unlabelled 8-33 ANP to normal rat plasma, was 91±4%. Nonspecific binding of the tracer was 3%. The sensitivity of the ANP-RIA was 3.3 pg/assay tube, with 50% displacement at 33 pg/assay tube.

Statistical analysis. Data are expressed as mean±SE. One-way analysis of variance was used to compare values for each parameter among normoxic + vehicle, normoxic + ANP (0.2 μg/h), hypoxic + vehicle, hypoxic + ANP (0.2 μg/h), and hypoxic + ANP (1 μg/h) groups. P<0.05 was considered significant.

Results

Rats exposed to hypoxia for 4 wk had significantly greater MPAP than air controls (33.9±0.6 mmHg vs. 17.1±0.5 mmHg, P<0.001) (Fig. 1, top). Chronic ANP infusion produced a dose-related decrease in MPAP in hypoxia-adapted rats. ANP infusion at doses of 0.2 and 1.0 μg/h reduced MPAP by a mean of 5.9 and 9.3 mmHg, ~ 17 and 27% of the vehicle control level and 35 and 55% of the hypoxia-induced increment in MPAP, respectively. In contrast, ANP (0.2 μg/h) did not lower MPAP in normoxic rats or MSAP in either hypoxic or normoxic rats (Fig. 1, middle). There was no difference in MSAP between the vehicle-treated hypoxic and normoxic groups. Rats exposed to hypoxia for 4 wk had reduced body weight compared to air controls (Fig. 1, bottom) but chronic ANP infusion had no additional effect on body wt. in either normoxic or hypoxic rats.

Chronic ANP infusion significantly reduced RV/body weight (BW) (Fig. 2, left top) and RV/LV+S (Fig. 2, right top) in a dose-related fashion in hypoxia-adapted rats, indicating that exogenous ANP attenuated the development of hypoxia-induced right ventricular hypertrophy. The percent reduction in RV/BW induced by ANP infusion was comparable to the percent decrease in MPAP. In contrast, ANP infusion (0.2 μg/h) did not significantly alter RV/BW in air-control rats. There was no significant difference in LV+S/BW between the vehicle-treated hypoxic and normoxic groups (Fig. 2, left bottom). Chronic ANP infusion produced a statistically insignificant increase in LV+S/BW in both the hypoxia-adapted and air-control rats at a dose of 0.2 μg/h and a significant increase at a dose of 1.0 μg/h in the hypoxic rats. The wall thickness of small pulmonary arteries (50–100 μm diam) was significantly greater in the hypoxic + vehicle group than in air controls (Fig. 2, right bottom). Chronic ANP infusion at both doses significantly decreased the wall thickness of these vessels.

Rats exposed to hypoxia for 4 wk and infused with vehicle had significantly greater (80%) increase) plasma ANP levels than air controls (Fig. 3, top). Hypoxia-adapted animals infused with ANP at the lower dose (0.2 μg/h) had only modest (60% of baseline, or 96 pg/ml) elevations in plasma ANP levels compared to vehicle-infused, hypoxic controls after 4 wk of ANP infusion. ANP infusion at the higher dose (1.0 μg/h) produced a 2.3-fold increase in plasma ANP in hypoxia-adapted rats.

The time course study revealed a fivefold elevation in plasma ANP compared to normoxic control levels on day 1 of
decreased MPAP, before infusion. ANP in and remained levels infusion BW, cP group. arterial pulmonary in 1. Figure 50% 0-% im Y 40O 0.01, compared the chronic infusion on 3, weight. concentrations of hypoxic (n 14. HYPOXC in incubated decrements in plasma ANP levels, which have no systemic depressor effect, attenuate the development of pulmonary hypertension and right ventricular hypertrophy in rats adapted to normobaric hypoxia. This is the first demonstration that chronically elevating circulating ANP levels by infusing exogenous peptide has a biologically important effect on the pulmonary circulation.

Our observation that plasma ANP levels were significantly elevated in vehicle-treated hypoxia-adapted rats compared with air controls confirms previous findings that hypoxia causes ANP release in vivo and in vitro (5–9, 22, 23). In the current study, chronic hypoxic exposure was associated with an 80% elevation in endogenous plasma ANP. Chronic infusion of exogenous ANP in doses that produced comparable elevations in plasma ANP levels attenuated the development of pulmonary hypertension and right ventricular hypertrophy in hypoxia-adapted rats. Taken together, the data suggest that endogenous ANP may play a role in the control of pulmonary artery pressure and in the pathogenesis of hypoxia-induced pulmonary hypertension, tending to attenuate the increase in pulmonary artery pressure induced by hypoxic adaptation.

ANP has a direct relaxant effect on pulmonary arterial smooth muscle in vitro (1, 2, 24, 25). Removal of the vascular endothelium does not alter this response, suggesting that it is not dependent on endothelium-derived relaxant factors (2, 24). Further, it has been reported that the vasorelaxant effects of ANP in the pulmonary artery are more potent than in the renal artery under the same conditions (2). The relaxant effect of ANP has been found to be 10 times more potent on pulmonary arteries than on renal arteries in isolated vascular preparations from pigs (25).

In vivo studies have documented that intravenous injection or infusion of ANP produces significant blunting of acute hypoxia-induced pulmonary vasoconstriction in rats, cats, dogs, and pigs (7, 13–15). Further, our previous studies demonstrated that bolus injection of ANP in conscious rats produces dose-related decreases in pulmonary artery pressure in both hypoxia-adapted and air-control animals (16). The pulmonary depressor effect of ANP is significantly increased in the hypoxic group compared with the air-control group. Further, we have previously shown that ANP lowers pulmonary

Figure 1. Effect of chronic ANP infusion on MPAP, MSAP, and BW in hypoxia-adapted rats. *P < 0.01, compared to the respective vehicle group. †P < 0.01, compared to the hypoxic + ANP (0.2 μg/h) group. ‡P < 0.01, compared to the normoxic group. MPAP = mean pulmonary arterial pressure. MSAP = mean systemic arterial pressure. BW, body weight.

infusion (Fig. 3, middle). Plasma ANP fell to 2.5 × control levels on day 3, plateaued at ~ 2 × control levels by day 10, and remained at that level on day 14. Survival of ANP dissolved in 0.1-M acetic acid and incubated at 37°C in vitro was ~ 50% of starting concentrations at 1–2 wk (Fig. 3, bottom). Further, the mean ANP concentration in the reservoirs of the spent minipumps was 246±33 ng/ml (n = 15), ~ 55% of the initial ANP concentration. This decrement was proportional to the percent decrease in plasma ANP levels between days 1 and 14 of ANP infusion. Thus, hydrolysis of ANP in the pump reservoirs likely accounts for the fall in plasma ANP levels seen during the course of the infusion.

Discussion

In the current study, chronic infusion of ANP for 4 wk beginning before the initiation of exposure to normobaric hypoxia decreased MPAP, RV/BW, and the ratio RV/LV+S at dose-related fashion compared to values in vehicle-treated hypoxia-adapted rats. ANP infusion was also associated with significant reductions in wall thickness of small (50–100 μm) pulmonary arteries, measured in a perfusion-fixed heart-lung preparation. ANP did not alter any of these parameters in air-control rats. The high dose (1.0 μg/h) ANP infusion reduced MPAP from 33.2±0.6 to 24.6±1.0 mmHg (P < 0.01); RV/BW from 1.04±0.02 to 0.88±0.03 mg/g (P < 0.01), and pulmonary vascular wall thickness from 22.1±0.4 to 19.8±0.5% (P < 0.05). The low-dose (0.2 μg/h) ANP infusion, which produced only a 60% elevation in plasma ANP levels compared to vehicle controls, also reduced MPAP, RV/BW, RV/LV+S, and wall thickness of small pulmonary arteries in hypoxia-adapted rats. The reductions in MPAP, RV/BW, and RV/LV+S were significantly greater with high- than with low-dose ANP; the effect on the pulmonary vessels was not dose-dependent.

Chronic ANP infusion did not significantly alter MSAP or body weight in either hypoxia-adapted or air-control rats. These results demonstrate that chronic ANP infusion attenuates the development of chronic hypoxia-induced pulmonary hypertension and right ventricular hypertrophy in a dose-dependent fashion and that increments in circulating ANP levels, which have no systemic depressor effect, attenuate the development of pulmonary hypertension and right ventricular hypertrophy in rats adapted to normobaric hypoxia. This is the first demonstration that chronically elevating circulating ANP levels by infusing exogenous peptide has a biologically important effect on the pulmonary circulation.

Our observation that plasma ANP levels were significantly elevated in vehicle-treated hypoxia-adapted rats compared with air controls confirms previous findings that hypoxia causes ANP release in vivo and in vitro (5–9, 22, 23). In the current study, chronic hypoxic exposure was associated with an 80% elevation in endogenous plasma ANP. Chronic infusion of exogenous ANP in doses that produced comparable elevations in plasma ANP levels attenuated the development of pulmonary hypertension and right ventricular hypertrophy in hypoxia-adapted rats. Taken together, the data suggest that endogenous ANP may play a role in the control of pulmonary artery pressure and in the pathogenesis of hypoxia-induced pulmonary hypertension, tending to attenuate the increase in pulmonary artery pressure induced by hypoxic adaptation.

ANP has a direct relaxant effect on pulmonary arterial smooth muscle in vitro (1, 2, 24, 25). Removal of the vascular endothelium does not alter this response, suggesting that it is not dependent on endothelium-derived relaxant factors (2, 24). Further, it has been reported that the vasorelaxant effects of ANP in the pulmonary artery are more potent than in the renal artery under the same conditions (2). The relaxant effect of ANP has been found to be 10 times more potent on pulmonary arteries than on renal arteries in isolated vascular preparations from pigs (25).

In vivo studies have documented that intravenous injection or infusion of ANP produces significant blunting of acute hypoxia-induced pulmonary vasoconstriction in rats, cats, dogs, and pigs (7, 13–15). Further, our previous studies demonstrated that bolus injection of ANP in conscious rats produces dose-related decreases in pulmonary artery pressure in both hypoxia-adapted and air-control animals (16). The pulmonary depressor effect of ANP is significantly increased in the hypoxic group compared with the air-control group. Further, we have previously shown that ANP lowers pulmonary
artery pressure significantly in isolated lungs from both hypoxia-adapted and air-control rats, and that this effect is significantly greater in the hypoxic than the air-control lungs. These findings suggest that ANP lowers pulmonary artery pressure in rats with hypoxia-induced pulmonary hypertension mainly by a direct vasodilator effect on the pulmonary vasculature (16). In addition, a recent clinical study has shown that incremental infusion rates of ANP in patients with pulmonary hypertension secondary to chronic obstructive lung disease causes dose-dependent vasodilation in the pulmonary circulation (26). After ANP infusion at the highest dose tested (0.1 μg/kg per min), pulmonary vascular resistance fell by 37%. Together with the current findings, these data raise the possibility that ANP may be useful in the treatment and prevention of hypoxic pulmonary hypertension in man.

ANP induces significant decreases in cardiac output in conscious and anesthetized rats and dogs (27–31). Most investigators believe that this fall in cardiac output is due to a reduction in venous return rather than a direct cardiac depressant action of ANP (31, 32). The mechanism by which ANP reduces venous return is uncertain and controversial. ANP has been reported to induce venodilation (28), leading to an augmentation of venous capacitance (31). In contrast, other observations suggest that ANP may increase resistance to venous return (29, 33, 34) via passive and active venuconstriction (34). In addition, ANP decreases plasma volume by shifting volume from the intravascular to the interstitial compartment (35). This may, in part, account for the ANP-induced reduction in venous return. The reduction in cardiac output could provide an additional mechanism for the pulmonary depressor effect of ANP in the hypoxia-adapted rat. However, recent studies have called into question the importance of the ANP-induced reduction in cardiac output in lowering pulmonary artery pressure in animals with hypoxic pulmonary hypertension. ANP infusion in doses that did not affect cardiac output markedly lowered pulmonary artery pressure and pulmonary vascular resistance in pigs exposed to acute hypoxia, indicating that the pulmonary depressor response to acute hypoxia in this model is not due to a reduction in cardiac output (7). Further, our previous studies demonstrated that MIPAP, MPAP, and cardiac output fell immediately after bolus injection of ANP in both hypoxia-adapted and air-control rats, whereas cardiac output in hypoxia-adapted rats was not different from that in weight-matched air controls. The reduction in MPAP was three times as great in hypoxia-adapted rats as in air controls (16). These findings suggest that the enhanced pulmonary depressor effect of ANP in hypoxia-adapted rats was not secondary to the reduction in cardiac output.

Alveolar hypoxia is a potent constrictor of pulmonary blood vessels (36), and exposure to chronic hypoxia causes smooth muscle cell growth and wall thickening in small peripheral pulmonary arteries (18, 37). Thus, the pulmonary hypertrophy and secondary RV hypertrophy observed in hypoxia-adapted rats in the current study may result from both functional constriction and anatomic wall thickening of the pulmonary vasculature. We observed that 4-wk exposure to normobaric hypoxia to doubling of MPAP and a 1.3-fold increase in RV/BW, respectively, but only a 46% increase in the wall thickness of small (50–100 μm) pulmonary arteries in both perfusion-fixed lung preparation, in which increased wall thickness reflects mainly morphological wall thickening, rather than active pulmonary vasoconstriction. Chronic ANP infusion at a dose of 1.0 μg/h reduced MPAP and RV/BW by 27 and 22%, respectively, but reduced the wall thickness of small (50–100 μm) pulmonary arteries by only 10% in the hypoxia-adapted rats; ANP had no effect on any of these parameters in air-control rats. It is likely that ANP lowers MPAP and RV/BW by attenuating both active vasoconstriction and morphological wall thickening of pulmonary vessels in hypoxia-adapted rats, whereas the ANP-induced reductions in pulmonary vascular wall thickness reflect decrements in morphological wall thickening only. This interpretation might
In summary, the current study demonstrated that chronic ANP infusion in a dose which produced only a modest elevation in plasma ANP levels attenuated the development of pulmonary hypertension and right ventricular hypertrophy and decreased the wall thickness of small (50–100 μm) pulmonary arteries in hypoxia-adapted rats. ANP had none of these effects in normoxic-control rats. Adaptation to chronic hypoxia for 4 wk was associated with an elevation in endogenous plasma ANP comparable in magnitude to that seen with the low-dose chronic ANP infusions. Further, infusion of ANP at a higher dose caused enhanced reductions in pulmonary artery pressure and right ventricular weight but no added effect on pulmonary arterial wall thickness. The data suggest that ANP may be involved in the regulation of pulmonary vascular tone in rats adapted to chronic hypoxia.

Acknowledgments

The excellent technical assistance of Joan Durand and editorial assistance of Charlene Crouse are gratefully acknowledged. We would also like to thank Wyeth Laboratories for providing the anti-ANP antibody.

This work was supported in part by research grants from the American Lung Association, the Council for Tobacco Research, USA, Inc., the Veterans Administration (VA) and NIH-NHLBI HL-39147, HL-22544, and HL-35051 (Specialized Center of Research in Hypertension). Dr. R. Jackson received an E. L. Trudeau Fellowship from the American Lung Association, and a Career Development Award from the VA Research Service.

References


